Cargando…

Novel biomarkers predict prognosis and drug-induced neuroendocrine differentiation in patients with prostate cancer

BACKGROUND: A huge focus is being placed on the development of novel signatures in the form of new combinatorial regimens to distinguish the neuroendocrine (NE) characteristics from castration resistant prostate cancer (CRPC) timely and accurately, as well as predict the disease-free survival (DFS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jingwei, Cai, Yingxin, Wang, Zuomin, Ma, Yuxiang, Pan, Jinyou, Liu, Yangzhou, Zhao, Zhigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849576/
https://www.ncbi.nlm.nih.gov/pubmed/36686485
http://dx.doi.org/10.3389/fendo.2022.1005916
_version_ 1784871989583806464
author Lin, Jingwei
Cai, Yingxin
Wang, Zuomin
Ma, Yuxiang
Pan, Jinyou
Liu, Yangzhou
Zhao, Zhigang
author_facet Lin, Jingwei
Cai, Yingxin
Wang, Zuomin
Ma, Yuxiang
Pan, Jinyou
Liu, Yangzhou
Zhao, Zhigang
author_sort Lin, Jingwei
collection PubMed
description BACKGROUND: A huge focus is being placed on the development of novel signatures in the form of new combinatorial regimens to distinguish the neuroendocrine (NE) characteristics from castration resistant prostate cancer (CRPC) timely and accurately, as well as predict the disease-free survival (DFS) and progression-free survival (PFS) of prostate cancer (PCa) patients. METHODS: Single cell data of 4 normal samples, 3 CRPC samples and 3 CRPC-NE samples were obtained from GEO database, and CellChatDB was used for potential intercellular communication, Secondly, using the “limma” package (v3.52.0), we obtained the differential expressed genes between CRPC and CRPC-NE both in single-cell RNA seq and bulk RNA seq samples, and discovered 12 differential genes characterized by CRPC-NE. Then, on the one hand, the diagnosis model of CRPC-NE is developed by random forest algorithm and artificial neural network (ANN) through Cbioportal database; On the other hand, using the data in Cbioportal and GEO database, the DFS and PFS prognostic model of PCa was established and verified through univariate Cox analysis, least absolute shrinkage and selection operator (Lasso) regression and multivariate Cox regression in R software. Finally, somatic mutation and immune infiltration were also discussed. RESULTS: Our research shows that there exists specific intercellular communication in classified clusters. Secondly, a CRPC-NE diagnostic model of six genes (HMGN2, MLLT11, SOX4, PCSK1N, RGS16 and PTMA) has been established and verified, the area under the ROC curve (AUC) is as high as 0.952 (95% CI: 0.882−0.994). The mutation landscape shows that these six genes are rarely mutated in the CRPC and NEPC samples. In addition, NE-DFS signature (STMN1 and PCSK1N) and NE-PFS signature (STMN1, UBE2S and HMGN2) are good predictors of DFS and PFS in PCa patients and better than other clinical features. Lastly, the infiltration levels of plasma cells, T cells CD4 naive, Eosinophils and Monocytes were significantly different between the CRPC and NEPC groups. CONCLUSIONS: This study revealed the heterogeneity between CRPC and CRPC-NE from different perspectives, and developed a reliable diagnostic model of CRPC-NE and robust prognostic models for PCa.
format Online
Article
Text
id pubmed-9849576
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98495762023-01-20 Novel biomarkers predict prognosis and drug-induced neuroendocrine differentiation in patients with prostate cancer Lin, Jingwei Cai, Yingxin Wang, Zuomin Ma, Yuxiang Pan, Jinyou Liu, Yangzhou Zhao, Zhigang Front Endocrinol (Lausanne) Endocrinology BACKGROUND: A huge focus is being placed on the development of novel signatures in the form of new combinatorial regimens to distinguish the neuroendocrine (NE) characteristics from castration resistant prostate cancer (CRPC) timely and accurately, as well as predict the disease-free survival (DFS) and progression-free survival (PFS) of prostate cancer (PCa) patients. METHODS: Single cell data of 4 normal samples, 3 CRPC samples and 3 CRPC-NE samples were obtained from GEO database, and CellChatDB was used for potential intercellular communication, Secondly, using the “limma” package (v3.52.0), we obtained the differential expressed genes between CRPC and CRPC-NE both in single-cell RNA seq and bulk RNA seq samples, and discovered 12 differential genes characterized by CRPC-NE. Then, on the one hand, the diagnosis model of CRPC-NE is developed by random forest algorithm and artificial neural network (ANN) through Cbioportal database; On the other hand, using the data in Cbioportal and GEO database, the DFS and PFS prognostic model of PCa was established and verified through univariate Cox analysis, least absolute shrinkage and selection operator (Lasso) regression and multivariate Cox regression in R software. Finally, somatic mutation and immune infiltration were also discussed. RESULTS: Our research shows that there exists specific intercellular communication in classified clusters. Secondly, a CRPC-NE diagnostic model of six genes (HMGN2, MLLT11, SOX4, PCSK1N, RGS16 and PTMA) has been established and verified, the area under the ROC curve (AUC) is as high as 0.952 (95% CI: 0.882−0.994). The mutation landscape shows that these six genes are rarely mutated in the CRPC and NEPC samples. In addition, NE-DFS signature (STMN1 and PCSK1N) and NE-PFS signature (STMN1, UBE2S and HMGN2) are good predictors of DFS and PFS in PCa patients and better than other clinical features. Lastly, the infiltration levels of plasma cells, T cells CD4 naive, Eosinophils and Monocytes were significantly different between the CRPC and NEPC groups. CONCLUSIONS: This study revealed the heterogeneity between CRPC and CRPC-NE from different perspectives, and developed a reliable diagnostic model of CRPC-NE and robust prognostic models for PCa. Frontiers Media S.A. 2023-01-05 /pmc/articles/PMC9849576/ /pubmed/36686485 http://dx.doi.org/10.3389/fendo.2022.1005916 Text en Copyright © 2023 Lin, Cai, Wang, Ma, Pan, Liu and Zhao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Lin, Jingwei
Cai, Yingxin
Wang, Zuomin
Ma, Yuxiang
Pan, Jinyou
Liu, Yangzhou
Zhao, Zhigang
Novel biomarkers predict prognosis and drug-induced neuroendocrine differentiation in patients with prostate cancer
title Novel biomarkers predict prognosis and drug-induced neuroendocrine differentiation in patients with prostate cancer
title_full Novel biomarkers predict prognosis and drug-induced neuroendocrine differentiation in patients with prostate cancer
title_fullStr Novel biomarkers predict prognosis and drug-induced neuroendocrine differentiation in patients with prostate cancer
title_full_unstemmed Novel biomarkers predict prognosis and drug-induced neuroendocrine differentiation in patients with prostate cancer
title_short Novel biomarkers predict prognosis and drug-induced neuroendocrine differentiation in patients with prostate cancer
title_sort novel biomarkers predict prognosis and drug-induced neuroendocrine differentiation in patients with prostate cancer
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849576/
https://www.ncbi.nlm.nih.gov/pubmed/36686485
http://dx.doi.org/10.3389/fendo.2022.1005916
work_keys_str_mv AT linjingwei novelbiomarkerspredictprognosisanddruginducedneuroendocrinedifferentiationinpatientswithprostatecancer
AT caiyingxin novelbiomarkerspredictprognosisanddruginducedneuroendocrinedifferentiationinpatientswithprostatecancer
AT wangzuomin novelbiomarkerspredictprognosisanddruginducedneuroendocrinedifferentiationinpatientswithprostatecancer
AT mayuxiang novelbiomarkerspredictprognosisanddruginducedneuroendocrinedifferentiationinpatientswithprostatecancer
AT panjinyou novelbiomarkerspredictprognosisanddruginducedneuroendocrinedifferentiationinpatientswithprostatecancer
AT liuyangzhou novelbiomarkerspredictprognosisanddruginducedneuroendocrinedifferentiationinpatientswithprostatecancer
AT zhaozhigang novelbiomarkerspredictprognosisanddruginducedneuroendocrinedifferentiationinpatientswithprostatecancer